Print

Active Biotech AB Interim Report January - March 2013

2013-04-25

Laquinimod
·first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of
relapsing-remitting multiple sclerosis
·data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced
early treatment with laquinimod compared with delayed treatment

Tasquinimod
·the Phase III study is proceeding according to plan

ANYARA
·Phase II/III study in renal cell cancer concluded
·Results presented:
- study did not achieve primary clinical endpoint
- doubling of progression-free survival and overall survival in 25 percent of patients
- planning of the continued clinical development ongoing

57-57 (paquinimod)
·clinical trial in systemic sclerosis concluded, evaluation underway

ISI
·focus on submission of patents

Other information
·Active Biotech raised SEK 270 M through a directed share issue to Investor

Jan - Mar Jan - Dec
(SEK M) 2013 2012 2012
  • Net sales
2.4 2.6 227.9
  • Operating loss
-77.0 -100.7 -163.2
  • Net loss
-78.0 -99.0 -175.0
  • Earnings per share (SEK)
-1.10 -1.44 -2.54

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech ABCorp. Reg. No. 556223-9227)
Box 724, SE-220 07
Lund
Tel: 046 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com


pdfActive Biotech AB : Interim Report January - March 2013



Back